Table 2.

Efficacy of therapy

Parameter	Thalidomide (N = 44)	Lenalidomide (N = 41)	Lenalidomide plus prednisone	P
Response				.06
Overall, median (%) [95% CI]	7 (16) [7-30]	14 (34) [20-51]	15 (38) [23-54]
CR, median (%) [95% CI]	1 (2) [0-12]	2 (5) [1-17]	2 (5) [1-7]
PR, median (%) [95% CI]	1 (2) [0-12]	5 (12) [4-26]	4 (10) [3-24]
CI, median (%) [95% CI]*	5 (12) [4-25]	7 (17) [7-32]	9 (23) [11-38]
Hemoglobin level, median (%) [95% CI]	5	4	4
Platelet count, median (%) [95% CI]	1	1	NA
ANC, median (%) [95% CI]	NA	NA	1
Spleen, median (%) [95% CI]	NA	3	4
Median follow-up (range), mo	116 (16-121)	57 (5-67)	42 (6 to ≥49)	< .0001
Median response duration (range), mo	13 (4-30)	7 (1-41)	34 (1 to ≥49)	.042
Median time to first response (range), wk	8 (3-15)	17 (2-29)	11 (2-45)	.0066
Median time to best response (range), wk	8 (3-32)	18 (2-39)	14 (2-79)	.0138

ANC indicates absolute neutrophil count; and CI, confidence interval.

^*Patients could have CI involving several lineages.